Data compiled by Redley Lamar · ChainSifter Intelligence
10Suppliers
11Customers
3Debt Items
10Related Chains
Source-Backed Evidence Depth
Oncotelic Therapeutics, Inc. (OTLC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
24Total relationships
5Distinct source URLs
12High confidence
0.768Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Oncotelic Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
MAST-HILL
MAST-HILL
92%
The Company entered into a Registration Rights Agreement with Mast Hill
MAST-HILL-FUND-LP
MAST-HILL-FUND-LP
92%
In July 2025, the Company entered into a securities purchase agreement with Mast Hill Fund LP ("Mast Hill"), under which the Company issued one convertible note in the aggregate principal amount of $…
JEFFERSON-CAPITAL-VENTURES-LLC
JEFFERSON-CAPITAL-VENTURES-LLC
90%
On January 6, 2026, Oncotelic Therapeutics, Inc. announced entering into an amendment to an independent contractor agreements with Jefferson Capital Ventures, LLC
LUNAI
LUNAI
90%
In consideration for the Merger, on May 1, 2026 Lunai issued to the Holders an aggregate of eight (8) shares of a newly designated series of preferred stock of the Company, designated as “Series B Co…
PELERIN
PELERIN
90%
The Series B Preferred Stock was allocated five (5) shares to the Company (representing 62.5% of the Series B Preferred Stock and an aggregate Stated Value of $12,500,000) and three (3) shares to Pel…
TECHFORCE-ROBOTICS-INC
TECHFORCE-ROBOTICS-INC
90%
The Agreement establishes a framework for the joint development, and manufacturing of AI-enabled, GMP-compliant robotic systems for use in pharmaceutical and related manufacturing environments. The i…
VALOR-NATION-INC
VALOR-NATION-INC
90%
In August, 2025, the Company entered into independent contractor agreements with each of Jefferson Capital Ventures, LLC ("Jefferson") and Valor Nation, Inc. ("Valor") to provide consulting and advis…
DRAGON-OVERSEAS-CAPITAL
DRAGON-OVERSEAS-CAPITAL
85%
In connection with the formation of the JV, the Company contributed license rights OT-101 for both U.S. and the rest of the world, in exchange for a 45% equity interest in GMP Biotechnology Limited (…
Reciprocal relationship from CPMV graph: Reciprocal relationship from OTLC graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from OTLC graph: Reciprocal relationship from CPMV g…
Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, …
Oncotelic Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
AUTOTELIC-INC
AUTOTELIC-INC
80%
The Company has agreed to issue to Autotelic, Inc. a number of shares of Common Stock equal to ten percent (10%) of the fully diluted outstanding shares of Oncotelic Therapeutics, Inc.
Reciprocal relationship from PPCB graph: Reciprocal relationship from OTLC graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions…
AUTOTELIC-INC-AUTOTELIC-INC
AUTOTELIC-INC-AUTOTELIC-INC
62%
gs merged with and into Merger Sub in a triangular merger (the “Merger”), with Merger Sub continuing as the surviving corporation and as a wholly owned subsidiary of Lunai. The Merger was completed o…
DRAGON-OVERSEAS-CAPITAL-LIMITED
DRAGON-OVERSEAS-CAPITAL-LIMITED
62%
incipal amount of $560,000 to Mast Hill (“ 2025 Mast Note ”). The 2025 Mast Hill Note has an original issue discount of 10%, carries an interest rate of 10% per annum and matures on the earlier of Ju…
GMP-BIOTECHNOLOGY-LIMITED
GMP-BIOTECHNOLOGY-LIMITED
62%
unicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) re…
GUIDELINE-PUBLIC-COMPANY
GUIDELINE-PUBLIC-COMPANY
62%
entered into the JV with Dragon, contributing a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP B…
JEFFERSON-CAPITAL-VENTURES-LLC
JEFFERSON-CAPITAL-VENTURES-LLC
62%
incipal amount of $560,000 to Mast Hill (“ 2025 Mast Note ”). The 2025 Mast Hill Note has an original issue discount of 10%, carries an interest rate of 10% per annum and matures on the earlier of Ju…
POINTR-DATA-INC
POINTR-DATA-INC
62%
The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. F- 22 The …
SAPU-HOLDINGS-LLC
SAPU-HOLDINGS-LLC
62%
entered into the JV with Dragon, contributing a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP B…
SHANGHAI-MEDICILON-INC
SHANGHAI-MEDICILON-INC
62%
entered into the JV with Dragon, contributing a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP B…
VALOR-NATION-INC
VALOR-NATION-INC
62%
incipal amount of $560,000 to Mast Hill (“ 2025 Mast Note ”). The 2025 Mast Hill Note has an original issue discount of 10%, carries an interest rate of 10% per annum and matures on the earlier of Ju…
Oncotelic Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OTLC-DEBT-11617
Warrants outstanding: 10576924
90%
xbrl warrant detail from xbrl 2024-09-30.
OTLC-DEBT-11618
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
OTLC-DEBT
Debt stack $2.7M
90%
Market cache reports total debt of $2.7M.
Oncotelic Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Oncotelic Therapeutics, Inc..
Oncotelic Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Oncotelic Therapeutics, Inc..
Oncotelic Therapeutics, Inc. Extended Supply Chain Network
